Archive for the Renal Cell Cancer category.
Since two drugs weren’t better than one, then why not try three drugs and see if that’s not better than one? Zapodian and Sella have both reported on a regimen using interleukin-2, interferon and 5-FU. This is a much more intense regimen, has to be given as an inpatient. Less intense regimens are typically given as an outpatient. They both initially reported 47% response rates. We haven’t heard much from the M.D. Anderson regimen since that, but Zapodian has consistently reported response rates in the 40% range. For lack of a better idea, this is what I treat my patients with, with metastatic disease. I use the Zapodian regimen as my initial regimen. If they fail that, then they are candidates for phase I studies. Certainly if you had a phase II trial that was ongoing or access to a phase II trial, that would be extremely appropriate treatment for patients with renal cell carcinoma as an initial treatment, reserving the interleukin-2, interferon approach for later.
Viagra professional
This is a report by a group looking at predictive factors for response to biological response modifiers and this group III here are patients with sarcomatoid histology regardless of their performance status, presence of bone metastases or whatever. In that group they had very poor response to biological based therapies. This is a summary, again from the M.D. Anderson paper, and those two patients who I mentioned earlier were then treated with a doxorubicin-containing chemotherapy and both of them actually received CY-VA-DACT which was the sarcoma regimen du jour back in the 70’s and 80’s when this data was collected. Of these eight patients, two went into complete remissions with chemotherapy and were still alive at the time that this paper was published, and they were in durable complete remission. So while sarcomatoid histology is a rare histology, it’s an important histology to be aware of because I believe some patients will have very dramatic and potentially be cured from their metastatic renal cell carcinoma with this diagnosis. This is an example of one of the patients that we treated when I was at Lombardi. This is a fellow with a sarcomatoid histology, had failed interleukin-2 and interferon and had a large mediastinal mass with pleural effusion and parenchymal lung nodule. And after the MAID chemotherapy, the mediastinal mass is gone as is the parenchymal lung disease. This patient is now - I think it’s about three years out - off treatment and continues in a complete remission.
Prostate cancer
I just want to say one word about some patients who have very poorly differentiated tumors at the time of diagnosis and have a clinically demonstrable, very rapidly progressing disease. Those patients I tend not to try to treat with immunotherapy. I think their course is just too aggressive. I’ve had some luck treating them as if they were poorly differentiated carcinomas of unknown primary. I don’t think there is anything in the literature about this yet, but just as a practical matter for you as you are out in practice, it’s something to consider.
Now there’s a study that’s still ongoing at the NIH looking at the high dose regimen versus the low dose intravenous regimen, versus the subcutaneous IL-2 regimen. And the response rates were initially thought to be fairly comparable but more recent analysis has really indicated that the high dose regimen is associated with a higher response rate and probably the more durable responses. The low dose regimens are probably not as effective, either from a response rate perspective or from a duration of response perspective.
Canadian pharmacy
The science that was driving this field for many years revolved around adoptive immunotherapy and it’s been difficult to do randomized trials using adoptive immunotherapy. Bob Figlund was able to carry out a randomized trial out of UCLA, which was a multi-center trial. Where they randomized patients to receive interleukin-2 plus the tumor-infiltrating lymphocytes around the tumor, versus interleukin-2 alone. That study showed basically no difference between the two groups. There’s also been another study using autologous lymphocyte therapy and that study was also negative for an effect. Some of the more interesting approaches, though, involves the use of mini-transplants where a high, but not typical bone marrow-type doses of chemotherapy are given, and then an allogeneic transplant is given with the idea of inducing a graft-versus-tumor response. Some of the initial data has been reported recently in JCO and this was the pattern of reconstitution in the patient that they reported on, and when they got T-cell reconstitution they started to have tumor regression which was complete. Eventually completed resolution of their disease. There’s a lot of work going on in this area. Other responses have been seen in renal cell carcinoma and this study is continuing at the NIH at the present time. These patients - if you are interested in referring somebody - this is an allogeneic program that requires a sibling as a match and there needs to be a five or six out of six match.
Order cheap cialis
Now some of the most interesting and promising preclinical data in history have revolved around this very fantastic synergy between interleukin-2 and interferon in mice. This resulted in a lot of interest in looking at this combination in the clinic. And a number of studies have been done combining interleukin-2 and interferon. This was a metaanalysis. It was done on four different studies and basically where there might have been some slight benefit for the combination, certainly the marked synergy that was seen in the preclinical models did not occur in the clinic. So, to be honest, this has been more disappointing than anything else although there is probably little reason not to combine both interleukin-2 and interferon. The results have not been what we had hoped.
This is the response duration curve and the median duration of response for the CR’s has not yet been met. There were only seven patients, but only three of them have relapsed. For the partial responses; there are a number of patients with partial responses who had very good partial responses, greater that 95% tumor shrinkage. Some of those patients probably simply had fibrous scar in an area that was still casting a shadow. But even in the partial responses some of these patients have had very durable responses. One point that I need to make, and may have been made also in some of the monoclonal antibody talks that you’ve had earlier, is that one of the initial thoughts was that with immunotherapy you could only expect to see shrinkage of very small tumors. That the immune system simply didn’t have enough oomph to it to cause regression of large tumors. In the experience with rituximab and certainly the experience with interleukin-2 has proven that simply not to be the case. Seems like the patients who are going to respond are going to respond almost regardless of the size of their tumor. Performance status is very important but with that caveat, that the patient has good performance status, the size of the tumor is not really a predictor of response.
Generic viagra online
On this slide, the number of patients who responded is plotted on the Y axis, and on the X axis is the tumor area in square centimeters. So the patients represented in this bar to the far right would have greater than 10×10 centimeter tumors because their total area was 100 square centimeters. This group would be greater than 7×7 and this would be greater than 5×5 centimeters. As you can see, if anything, there is a weighting of patients to this side of the curve. Clearly not all of these patients are simply patients with small one or two centimeter pulmonary nodules.
Generic Prilosec
So it seems that the patients who are going to respond to this treatment are going to respond and it’s very hard to predict in advance who is going to respond and who is not going to. And that’s important because this treatment, as approved by the FDA and is outlined in the package insert, is incredibly toxic and you cannot really give this treatment without being willing to make these patients extremely sick - if you are going to give it by the approved package insert. To do this you need to be in an institution that has a very good intensive care group and an intensive care group that is interested in managing these patients. Because the side effects of interleukin-2 really mimic those of septic shock. Septic shock being primarily manifested by cytokine production. It’s not surprising that treating patients with high doses of interleukin-2 would mimic that appearance. Almost all these patients will have hypertension. In many will be very significant, about three-quarters requiring pressor support. Mental status changes are common; 5% of the patients in this series developed grade IV mental status changes. That’s frank psychosis often requiring four-point restraints. Some of the patients became comatose, some of the patients developed respiratory failure requiring ventilatory support. And the patients who died from the treatment were patients who developed infections near the end of their treatment course. It’s easy to overlook these infections because the fever and the hypotension is something that you also get from the interleukin-2. But it’s in those patients who wind up dying from this high dose treatment. So this is not for the faint-of-heart, either by the patient or by the treating physician, and there are centers in the country who do this on a regular basis, and I think you really have to consider sending them to one of those centers unless you are planning to make this a major focus of your practice.
The other drug that has been tried in renal cell carcinoma is alpha interferon and a large number of investigators have looked at a large number of interferon preparations. Generally, in the regimens that you can give as an outpatient and are tolerated by the patients, I think a response rate of about 10-15% is a reasonable number to carry around in your head. Most of these response durations are fairly short-lived although there are a very rare occasional patient who will have a prolonged good response to interferon. But generally, as you know, interferon is a fairly toxic treatment and really does not result in an improved quality of life for the patients, suffering from the side effects of the interferon. So it’s difficult to get very excited about interferon as a single agent, especially for any kind of prolonged treatment course. Patients who tend to respond to interferon are the ones who have a good performance status prior to nephrectomy, non-bulky pulmonary and soft tissue metastases and patients who are asymptomatic or who have minimal symptomatology. So it is exactly the group that you would be most hesitant to make sick from the interferon, that would be likely to respond. So you need to come to grips with this problem philosophically on your own.
Generic soma online
The other thing I need to touch upon is the frequency of spontaneous remissions. There’s been a lot of talk about this in the literature and when Bloom reviewed 1,100 patients back in 1973 - his own group of 195 patients and then six other studies - and reported on the times that spontaneous regressions were reported in these studies. He found two in his own series where he was specifically looking for it and then one in the other series where they were not specifically looking for it and concluded that the incidence of spontaneous remissions was 0.3%. I think probably a better figure, although this is really virtue among thieves, is two out of 195 where he was specifically looking for it. So the incidence is probably around 1%. But I think that carrying a figure of 0.3% to 1% incidence of spontaneous remissions is probably an accurate number. So clearly you would not be doing nephrectomies trying to get that kind of a response rate. Interestingly, when the natural history of the spontaneous remissions is reviewed, 19 out of 51 of these cases that were reviewed were histologically confirmed. Most of them were in the lung. Thirty-seven of the responses came after nephrectomy and four came after radiation to the kidney. So about 80% of these spontaneous remissions occurred after some treatment to the kidney. And of these 51 patients, 29 had a duration of response and follow-up greater than two years. So when these occur they can sometimes be very significant. But you certainly don’t want to plan your treatment regimen around the development of this. It is worthwhile though, in patients who present with a renal cell carcinoma that’s metastatic, it’s sometimes very useful to just observe those patients especially if they are elderly and couldn’t tolerate treatment, and get some sense of the pace of their disease. It can be very variable. I’ve had patients whose tumors have grown over a three-month period, we were concerned that we were going to have to start chemo or some kind of treatment for their metastatic disease, decided to follow them - mostly because of usually personal reasons, they wanted to wait for a little bit, they were asymptomatic - so three months later there was no change in the lesions that had previously been progressing. So if I’ve put somebody, put those people on treatment, at that point I would have said, “Wow, we’ve interrupted the growth of your tumor.” So you really do need to get a sense of the pace of the disease that you are dealing with.
Canadian Pharmacy
Now it was in this context that interleukin-2 came on the scene and as you know, interleukin-2 is a T-cell growth factor. The clinical material is a 15.5 kilodalton peptide and obviously in vivo it’s produced by the helper T-cells. In May of 1992 the FDA approved interleukin-2 for the treatment of metastatic renal cell carcinoma. This is the only FDA-approved treatment for metastatic renal cell carcinoma, or for renal cell carcinoma in general. The regimen was a very high dose regimen that was developed at the National Cancer Institute in the surgery branch by Steve Rosenberg and that regimen was developed in the context of giving adoptive immunotherapy. The clinical trials that supported approval were using that same IL-2 regimen but without the adoptive immunotherapy. So evaluated in 255 patients both at the surgery branch and in some extramural studies, and there was an overall response rate of 15%. Not strikingly different from that of the interferon. So why has interleukin-2 been approved and interferon has not been approved for renal cell carcinoma? It’s because the median duration of these responses was about two years and some of these patients had apparently extremely durable complete responses and probably are cured from their renal cell carcinoma. These are just the response data.
Canadian Health&Care Mall
Now the role of surgery in renal cell carcinoma is a little controversial. I think probably more controversial with me than perhaps with other speakers you may have up here. But certainly in stage I and II radical nephrectomy is the only effective therapy. Regional lymphadenectomy provides no clear survival benefit, although clearly there would be prognostic information gained if the regional lymph nodes were sampled. Especially if more than one lymph node was involved, I think given the natural history of this disease those patients would be stage IV NED if the patient was young and otherwise healthy, you’d have to consider at least potentially treating at that point. Although there is no data yet on that. For stage III, sometimes the tumor can be going up the inferior vena cave and very aggressive surgery, including cardiopulmonary bypass support is indicated in these patients. The presence of vascular thrombi in the inferior vena cava is not necessarily a poor prognostic factor. If you have tumor invasion into the vessel, into the inferior vena cava, that’s a different story. But if you just have clot propagated up the cava, that is not necessarily a poor prognostic factor and these patients do need aggressive surgery.
Canadian pharmacy viagra
For stage IV, the party line is that you do a palliative nephrectomy only for symptoms. I think this is still considered probably to be the standard answer to this question. So if patients are having hematuria or pain, a nephrectomy would be indicated for that. There is some experience in patients who have had resection of solitary, especially pulmonary, metastases that occur a long time after having their initial diagnosis. There is a role for surgery in that situation. I personally believe that these patients in general do better with a nephrectomy than without a nephrectomy. So the urologists love to consult me because I always recommend that patients undergo a nephrectomy. But I do think that in general if the patient is in reasonable health, the nephrectomy is a procedure that, in general, patients recover from fairly quickly. It’s a retroperitoneal dissection. The bowel is not violated and the recovery is usually pretty quick. And especially patients who have a fairly large primary tumor, even if those patients are asymptomatic at the time of presentation and they have metastatic disease, I typically will still recommend that those patients undergo a nephrectomy. I think they are in the best shape that they are going to be in right at that period of time. It’s a cellular bulk disease that you don’t have to contend with later, and if they do become symptomatic, frequently at that point their performance status is so poor that trying to do a nephrectomy at that time is very difficult. There are some people who believe that they respond better to immunotherapy or other treatment regimens if the kidney is out as well. That’s still an open point, but I think that in general I tend to recommend a nephrectomy even in the face of metastatic disease; assuming that the patients are reasonable surgical candidates.
Canadian pharmacy cialis
Now as far as treatment of metastatic disease; I think you are all aware that chemotherapy has little activity, as reported in the literature, in this disease. This is some data that Phil Keebler reviewed a number of years ago and reports the dismal activity of a number of different agents in renal cell carcinoma. There was some activity reported in a small series of patients with FUDR, patients who had been treated with nitrosoureas and vinblastine have response rates of less than 10%. Although these regimens were used a lot when I was in my training. The responses to hormonal therapy, I think, are also dismal. We sometimes will put patients on megestrol for their appetite. But I think that that’s pretty much all you are doing. Again, when I was in training there was some thought that hormones potentially did do something in this disease. The natural history of renal cell carcinoma is extremely variable. In this review that occurred in 1983 there was an overall 8% response rate reported to a variety of different hormonal types of manipulations. I think you have to realize also that the clinical trials methodology back when these studies were conducted is not what it is now. Some of these response rates, I think these response rates even at the 8% level, are unfortunately probably inflated somewhat. So I think that the true response rate is probably closer to half of that … if that.
Presentations; typically about half the patients will present with stage I or II disease. I think we are seeing more and more patients presenting with an incidental finding of renal cell carcinoma, because they are having CAT scans of the abdomen obtained for various reasons, and we are seeing patients in whom renal cell carcinomas are picked up incidentally on those scans. About one-quarter of the patients present with stage III disease and about one-quarter present with stage IV disease. Now Stauffer, in 1960-something, described a syndrome where patients with apparently disease isolated to the kidney presented with systemic constitutional symptoms and also liver function abnormalities. In this small series of seven patients, five of those patients presented with fever, six presented with weight loss, six presented with fatigue and 72% had all three; fever, fatigue and weight loss. This syndrome now I think is recognized to be due to cytokine production, possibly the production of IL-6. But in patients with liver function abnormalities but no evidence of metastases elsewhere, or certainly liver metastases, this complete syndrome can be successfully treated with surgery. And the liver function abnormalities will return to normal; fever, weight loss and fatigue will disappear upon resection of the kidney. So there are patients who present with systemic illness which you would sort of intuitively think had widespread metastatic disease, but those patients may well benefit considerably from a nephrectomy and may not need further treatment.
Now I mentioned briefly the sarcomatoid variant of renal cell carcinoma. Again, this is a variant of the clear cell type. Renal cell carcinoma itself is rare and of the renal cell carcinomas, only 5% or so represent sarcomatoid histology. So this is a rare tumor but I think it’s important to be aware of it. The cells have a sarcomatoid appearance and the way you can distinguish this tumor from a sarcoma of the kidney is that the sarcoma of the kidney will not have any clear cell features associated with it. It will be a pure sarcoma. The sarcomatoid variant will have some areas, maybe fairly small, but will have some areas that are typical of renal cell carcinoma, the more traditional cellular appearance. This is the survival curve for patients with sarcomatoid variant and this upper curve is the survival curve for patients with non-sarcomatoid variant. You can see that the sarcomatoid variant has a very dismal prognosis, median survival here being a number of months, just a few months. Another important point about sarcomatoid variant is that of the patients who presented with stage I-III disease - this is an article from M.D. Anderson, I think in the 80’s - where they reviewed 44 cases of sarcomatoid variant. They had 19 that presented with stage I-III disease and none of these patients were cured with nephrectomy alone. All of these patients relapsed. The two patients who were alive an in a durable complete remission were patients who relapsed and then were treated successfully with chemotherapy.
Generic levitra
There is a relationship between the proportion of the tumor that exhibits the sarcomatoid pattern. These two lines represent patients whose tumor was either 50% sarcomatoid and 50% regular renal cell carcinoma or greater, and then one of these lines is 75%. So when you have more than 50% of the tumor as a sarcomatoid histology you need to consider that patient as having a sarcomatoid histology. This line here was for patients who had less than 25% of the histologic specimen showing sarcomatoid variant.
Order Acomplia
Now when patients develop metastatic disease, there’s a number of papers that have been written about how to assess their prognosis. And to be honest, these papers I think have been used primarily when pharmaceutical companies are trying to come up with a historical control group to compare for their studies, but they are useful to recognize. There’s really no surprises here. These are the major risk factors for poor prognosis and ECOG performance status, a poor ECOG performance status is a very significant risk factor. Time from diagnosis less than a year, two or more metastatic sites, prior cytotoxic chemotherapy and weight loss in the previous six months. These were data from 610 patients who were treated on Eastern Cooperative Oncology Group studies for renal cell carcinoma, and they were able to identify an algorithm that they felt helped differentiate the survival of these patients. But still the patients who had the best prognosis still only had a median survival of about 12 months. More recently in the Journal of Clinical Oncology this year another analysis was done looking at LDH, hemoglobin, calcium, the Karnofsky performance status and the prior nephrectomy were identified as risk factors in patients with metastatic disease, poor prognostic factors in patients with metastatic disease. These were the curves that they were able to generate, based on whether patients had no risk factors, one or two, three or more risk factors. So none of these things are surprising but it may help you in counseling your patients.
Canadian pharmacy